Presentation Transcript

1. Genital Human Papillomavirus (HPV) Infection Edward L. Goodman, MD February 23, 2005

2. Case Study History • Anne Drew: 34-year-old woman who wants to get "checked out" because Jonathan, her sex partner, has small solid "bumps" on the skin on the shaft of his penis • Jonathan told her that he was diagnosed and treated for genital warts about a year ago, and his health care provider told him they could recur. • No history of abnormal Pap smears and no history of STDs • Last Pap smear performed 4 months ago • Sexually active with men only since age 16; has had a total of 7 sex partners over her lifetime • Currently sexually active with 1 partner for the last 8 months • Uses oral contraceptives for birth control

3. Case Study Physical Examination • Vital signs: blood pressure 96/74, pulse 78, respiration 13, temperature 37.1° C • Cooperative, good historian • Chest, heart, musculoskeletal, and abdominal exams within normal limits • Pelvic exam is normal • Visual inspection of the genitalia reveals multiple small (<0.5 cm), flesh-colored, papular lesions in the perineal area

4. Clinical Manifestations Perianal Warts Source: Seattle STD/HIV Prevention Training Center at the University of Washington/ UW HSCER Slide Bank

5. Clinical Manifestations Vulvar Warts Source: Reprinted with permission of Gordon D. Davis, MD.

6. Lessons • Epidemiology of genital HPV infection in the U.S. • Pathogenesis • Clinical manifestations and sequelae • Diagnosis of genital warts and cervical cellular abnormalities • Patient management • Patient counseling and education • Partner management and public health measures

7. Lesson I: Epidemiology of Genital HPV Infection in the U.S.

8. Epidemiology Introduction • Genital HPV is one of the most common STDs. • More than 30 HPV types can infect the genital tract.

9. 1 Million New Genital Herpes (GH) Infections per Year in the US Genital Herpes is the Most Prevalent STD Chlamydia 2 million Hepatitis B 417,000 HPV 20 million HIV 560,000 Genital Herpes (HSV-2) 45 million Henry J. Kaiser Family Foundation. CDC Web site. Tracking the hidden epidemics: trends in STDs in the United States 2000:1-31. Xu, F. CDC. NHANES 1999-2002, Oral Presentation. IDSA, Boston 2004.

10. Epidemiology Introduction • HPV types are divided into 2 groups based on their association with cervical cancer: • Low-risk types associated with genital warts and mild Pap test abnormalities • High-risk types associated with mild to severe Pap test abnormalities and cervical cancer • Most genital HPV infections are transient, asymptomatic, and have no clinical consequences.

11. Epidemiology Incidence in the U.S. • Estimated annual incidence of sexually transmitted HPV infection is 6.2 million • Estimated $1.6 billion spent annually in direct medical costs to treat symptoms of genital HPV infection • Estimated 20 million people currently have a detectable genital HPV infection

12. Epidemiology Prevalence in the U.S. • It is estimated that at least 50% of sexually active men and women acquire genital HPV at some point in their lives. • A recent estimate suggests 80% of women will have acquired genital HPV by the age of 50.

13. Epidemiology Incidence and Prevalence of HPV-associated Diseases • Genital warts • Incidence may be as high as 100/100,000. • An estimated 1.4 million are affected at any one time. • Cervical cancer • Rates of cervical cancer have fallen by approximately 75% since the introduction of Pap screening programs. • Incidence is estimated at 8.3/100,000.

14. Epidemiology Transmission of Genital HPV • Predominantly associated with sexual activity • Can occur from asymptomatic and subclinical patients • Infectivity after treatment of genital warts or cervical cell abnormalities is unknown

15. Epidemiology Risk Factors for Women • Young age (34) • Sexual behavior • Risk increases with increasing lifetime number of male sex partners (Seven life time partners) • Early age of first sexual intercourse (Age 16) • Sexual behavior of male sex partners–risk increases for women whose sex partners had multiple sex partners (he has history of warts) • Immune status–HPV more likely to be detected in immune-suppressed women

16. Risk Factors for Incident HPV Infection in College WomenHo, G. Y.F. et al. N Engl J Med 1998;338:423-428

17. Risk Factors for Persistence of HPV Infection for >6 Months in College Women Ho, G. Y.F. et al. N Engl J Med 1998;338:423-428

18. Epidemiology Risk Factors for Men • Greater lifetime number of sex partners • Greater number of recent sex partners • Being uncircumcised

19. Pathogenesis Virology • Double-stranded DNA virus that belongs to the Papovaviridae family • Genital types have specific tropism (affinity) for genital skin and mucosa • Infection generally indicated by the detection of HPV DNA or capsid protein

20. Pathogenesis HPV Genotyping System • Low-risk types • Most visible warts caused by HPV types 6 and 11 • Recurrent respiratory papillomatosis associated with HPV types 6 and 11 • High-risk types • HPV types 16 and 18 found in more than half of anogenital cancers • Most women with high-risk HPV infection have normal Pap test results and never develop precancerous cell changes or cervical cancer

21. Pathogenesis Pathology • HPV infects stratified squamous epithelium and stimulates cellular proliferation. • Affected cells display a broad spectrum of changes ranging from benign hyperplasia to dysplasia to invasive carcinoma.

22. Pathogenesis Natural History of HPV • Most genital HPV infections are transient, asymptomatic, or subclinical, and have no clinical consequences in immunocompetent individuals. • The incubation period is unclear. • The median duration of new cervical infections is 8 months but varies by type. • Gradual development of an effective immune response is the likely mechanism for HPV DNA clearance.

23. Pathogenesis Natural History of HPV (continued) • Persistent infection is infection that is not cleared by the immune system and is characterized by persistently detectable HPV DNA. • HPV infection that persists is the most important factor for precancerous cervical cell changes and cervical cancer. • Most women with persistent HPV infection do not develop cervical cancer precursors or cervical cancer.

24. Clinical Manifestations Clinical Manifestations and Sequelae • In most cases, genital HPV infection is transient and has no clinical manifestations or sequelae. • Clinical manifestations of genital HPV infection include: • Genital warts • Cervical cell abnormalities • Anogenital squamous cell cancers • Recurrent respiratory papillomatosis • Most common clinically significant HPV infection manifestations: • Genital warts • Cervical cell abnormalities

25. Clinical Manifestations Genital Warts: Appearance • Condylomata acuminata • Cauliflower-like appearance • Skin-colored, pink, or hyperpigmented • May be keratotic on skin; generally non-keratinized on mucosal surfaces • Smooth papules • Usually dome-shaped and skin-colored • Flat papules • Macular to slightly raised • Flesh-colored, with smooth surface • More commonly found on internal structures (i.e., cervix), but also occur on external genitalia • Keratotic warts • Thick horny layer that can resemble common warts or seborrheic keratosis

26. Clinical Manifestations Genital Warts: Location • Warts commonly occur in areas of coital friction. • Perianal warts do not necessarily imply anal intercourse. • May be secondary to autoinoculation, sexual activity other than intercourse, or spread from nearby genital wart site. • Intra-anal warts are seen predominantly in patients who have had receptive anal intercourse. • Patients with visible warts can be simultaneously infected with multiple HPV types.

27. Clinical Manifestations Vulvar Warts Source: Reprinted with permission of Gordon D. Davis, MD.

28. Clinical Manifestations Perianal Warts Source: Seattle STD/HIV Prevention Training Center at the University of Washington/ UW HSCER Slide Bank

29. Clinical Manifestations Penile Warts Source: Cincinnati STD/HIV Prevention Training Center

30. Clinical Manifestations Intrameatal Wart Source: Cincinnati STD/HIV Prevention Training Center

31. Clinical Manifestations Genital Warts: Symptoms • Genital warts usually cause no symptoms other than the warts themselves. • Vulvar warts--dyspareunia, pruritis, burning discomfort • Penile warts--occasional itching • Urethral meatal warts--occasional hematuria or impairment of urinary stream • Vaginal warts--usually asymptomatic; occasional discharge/bleeding, obstruction of birth canal (secondary to increased wart growth during pregnancy) • Perianal warts--usually asymptomatic; pain, bleeding on defecation, itching • Most patients have fewer than 10 genital warts, with total wart area of 0.5-1.0 cm2.

32. Clinical Manifestations Genital Warts: Duration • May regress spontaneously or persist with or without proliferation. • Frequency of spontaneous regression is unclear. • Persistence of infection occurs, but frequency and duration are unknown. • Recurrences after treatment are common.

33. Clinical Manifestations Genital Warts and High-Risk HPV • High-risk HPV types occasionally found in visible genital warts • Associated with external genital (i.e., vulvar, penile, and anal) squamous intraepithelial lesions

34. Clinical Manifestations Cervical Cell Abnormalities • Usually subclinical • Detected by Pap test, colposcopy, or biopsy • Usually caused by high-risk HPV types • Most of the time high-risk HPV types do not cause any abnormalities. • Most women infected with high-risk HPV types have normal Pap test results. • Often regress spontaneously without treatment

35. Clinical Manifestations Anogenital Squamous Cell Cancers • HPV infection is causally associated with cervical cancer and probably other anogenital squamous cell cancers (e.g., anal, penile, vulvar, vaginal). • Over 99% of cervical cancers have HPV DNA detected within the tumor. • Persistent infection with a high-risk HPV type is necessary but not sufficient for the development of cervical cancer.

36. Diagnosis Diagnosis of Genital Warts • Diagnosis is usually made by visual inspection with bright light. • Diagnosis can be confirmed by biopsy when: • Diagnosis is uncertain • Patient is immunocompromised • Warts are pigmented, indurated, or fixed • Lesions do not respond or worsen with standard treatment • There is persistent ulceration or bleeding

37. Diagnosis Diagnosis of Genital Warts(continued) • Use of type-specific HPV DNA tests for routine diagnosis and management of genital warts is not recommended. • Acetic acid evaluation (acetowhitening) of external genitalia is not recommended. • External genital warts are not an indication for cervical colposcopy or increased frequency of Pap test screening (assuming patient is receiving screening at intervals recommended by her health care provider).

38. Diagnosis Differential Diagnosis of Genital Warts • Other infections • Condylomata lata--tend to be smoother, moist, more rounded, and darkfield-positive for Treponema pallidum • Molluscum contagiosum--papules with central dimple, caused by a pox virus; rarely involves mucosal surfaces

39. Diagnosis Differential Diagnosis of Genital Warts (continued) • Acquired dermatologic conditions • Seborrheic keratosis • Lichen planus • Fibroepithelial polyp, adenoma • Melanocytic nevus • Neoplastic lesions • Normal anatomic variants • “Pink pearly penile papules” • Vestibular papillae (micropapillomatosis labialis) • Skin tags (acrochordons)

40. Diagnosis Diagnosis of Cervical Cell Abnormalities • Cytology (Pap test) • Useful screening test to detect cervical dysplasia (not HPV per se) • Provides indirect evidence of HPV because it detects squamous epithelial cell changes that are almost always due to HPV

41. Diagnosis Diagnosis of Cervical Cell Abnormalities (continued) • Nucleic acid testing • FDA-approved for two optional uses: • To triage women with atypical cells of undetermined significance (ASC-US) Pap test results • As an adjunct to the Pap test to screen for cervical cancer in women 30 years or older. • Use of HPV DNA testing for women with SIL Pap test results is unnecessary because the vast majority of women with SIL are infected with HPV.

42. Algorithm for Integration of Pap/HPV testingKulasingam and Koutsky. Curr Inf Dis Rep 2001;3:169-180

43. Algorithm continued

45. Management General Treatment of Genital Warts • Primary goal is removal of symptomatic warts. • If left untreated, genital warts may regress spontaneously or persist with or without proliferation. • In most patients, treatment can induce wart-free periods. • Currently available therapies may reduce, but probably do not eradicate infectivity. • Effect of current treatment on future transmission is unclear.

46. Management General Treatment of Genital Warts (continued) • No evidence that presence of genital warts or their treatment is associated with development of cervical cancer. • Some patients may choose to forgo treatment and await spontaneous resolution. • Consider screening persons with newly diagnosed genital warts for other STD (e.g., chlamydia, gonorrhea, HIV, syphilis). • This is a general principle: one STD suggests need for search for other STD

47. Management Treatment Regimens • Patient-applied and provider-administered therapies are available. • Providers should be knowledgeable about and have available at least 1 patient-applied and 1 provider-administered treatment. • Choice of treatment should be guided by: • The preference of the patient • The available resources • The experience of the healthcare provider

48. Management Treatment Regimens(continued) • Factors influencing treatment selection: • Wart size • Number of warts • Anatomic site of wart • Wart morphology • Patient preference • Cost of treatment • Convenience • Adverse effects

49. Management Treatment Response • Affected by: • Number, size, duration, and location of warts, and immune status • In general, warts located on moist surfaces and in intertriginous areas respond better to topical treatment than do warts on drier surfaces. • Many patients require a course of therapy rather than a single treatment. • Evaluate the risk-benefit ratio of treatment throughout the course of therapy to avoid over-treatment. • No evidence that any specific treatment is superior to any of the others. • The use of locally developed and monitored treatment algorithms has been associated with improved clinical outcomes.

50. Management Recurrence • Up to 2/3 of patients will experience recurrences of warts within 6-12 weeks of therapy; after 6 months most patients have clearance. • If persistent after 3 months, or if there is poor response to treatment, consider biopsy to exclude a premalignant or neoplastic condition, especially in an immunocompromised person. • Treatment modality should be changed if patient has not improved substantially after 3 provider-administered treatments or if warts do not completely clear after 6 treatments.

Load More ...